BIO GREEN MED SOLUTION INC (BGMS) Stock Fundamental Analysis

NASDAQ:BGMS • US23254L8761

1.07 USD
+0.04 (+3.88%)
At close: Feb 18, 2026
1.06 USD
-0.01 (-0.93%)
Pre-Market: 2/19/2026, 9:10:38 AM
Fundamental Rating

3

BGMS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. BGMS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BGMS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BGMS has reported negative net income.
  • BGMS had a negative operating cash flow in the past year.
  • BGMS had negative earnings in each of the past 5 years.
  • In the past 5 years BGMS always reported negative operating cash flow.
BGMS Yearly Net Income VS EBIT VS OCF VS FCFBGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • BGMS has a worse Return On Assets (-85.49%) than 69.87% of its industry peers.
  • BGMS has a Return On Equity (-98.28%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BGMS Yearly ROA, ROE, ROICBGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • BGMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGMS Yearly Profit, Operating, Gross MarginsBGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

6

2. Health

2.1 Basic Checks

  • BGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BGMS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BGMS has been increased compared to 5 years ago.
  • BGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGMS Yearly Shares OutstandingBGMS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
BGMS Yearly Total Debt VS Total AssetsBGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -76.18, we must say that BGMS is in the distress zone and has some risk of bankruptcy.
  • BGMS's Altman-Z score of -76.18 is on the low side compared to the rest of the industry. BGMS is outperformed by 93.09% of its industry peers.
  • There is no outstanding debt for BGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -76.18
ROIC/WACCN/A
WACC8.69%
BGMS Yearly LT Debt VS Equity VS FCFBGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • A Current Ratio of 6.43 indicates that BGMS has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.43, BGMS is doing good in the industry, outperforming 65.64% of the companies in the same industry.
  • A Quick Ratio of 5.07 indicates that BGMS has no problem at all paying its short term obligations.
  • With a Quick ratio value of 5.07, BGMS perfoms like the industry average, outperforming 57.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 5.07
BGMS Yearly Current Assets VS Current LiabilitesBGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 96.34% over the past year.
  • BGMS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.46%.
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%

3.2 Future

  • The Earnings Per Share is expected to grow by 57.16% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BGMS will show a very strong growth in Revenue. The Revenue will grow by 1049.89% on average per year.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A

3.3 Evolution

BGMS Yearly Revenue VS EstimatesBGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2023 2024 2025 2026 2027 20M 40M 60M 80M
BGMS Yearly EPS VS EstimatesBGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -100K -200K -300K

1

4. Valuation

4.1 Price/Earnings Ratio

  • BGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BGMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGMS Price Earnings VS Forward Price EarningsBGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGMS Per share dataBGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BGMS's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

0

5. Dividend

5.1 Amount

  • No dividends for BGMS!.
Industry RankSector Rank
Dividend Yield 0%

BIO GREEN MED SOLUTION INC

NASDAQ:BGMS (2/18/2026, 8:15:57 PM)

Premarket: 1.06 -0.01 (-0.93%)

1.07

+0.04 (+3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-31
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners62.28%
Ins Owner Change11.22%
Market Cap5.24M
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Analysts43.33
Price TargetN/A
Short Float %4.14%
Short Ratio0.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)58.82%
Min Revenue beat(2)-100%
Max Revenue beat(2)217.65%
Revenue beat(4)1
Avg Revenue beat(4)-20.59%
Min Revenue beat(4)-100%
Max Revenue beat(4)217.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 64.73
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-80.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.02
BVpS1.45
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 5.07
Altman-Z -76.18
F-Score5
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y40.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIO GREEN MED SOLUTION INC / BGMS FAQ

What is the ChartMill fundamental rating of BIO GREEN MED SOLUTION INC (BGMS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGMS.


Can you provide the valuation status for BIO GREEN MED SOLUTION INC?

ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION INC (BGMS). This can be considered as Overvalued.


How profitable is BIO GREEN MED SOLUTION INC (BGMS) stock?

BIO GREEN MED SOLUTION INC (BGMS) has a profitability rating of 0 / 10.


How financially healthy is BIO GREEN MED SOLUTION INC?

The financial health rating of BIO GREEN MED SOLUTION INC (BGMS) is 6 / 10.